company background image
A128940 logo

Hanmi Pharm KOSE:A128940 Stock Report

Last Price

₩287.00k

Market Cap

₩3.6t

7D

6.1%

1Y

4.7%

Updated

07 Jul, 2024

Data

Company Financials +

Hanmi Pharm. Co., Ltd.

KOSE:A128940 Stock Report

Market Cap: ₩3.6t

A128940 Stock Overview

A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.

A128940 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Hanmi Pharm. Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hanmi Pharm
Historical stock prices
Current Share Price₩287,000.00
52 Week High₩377,000.00
52 Week Low₩256,372.55
Beta0.55
11 Month Change-3.04%
3 Month Change-7.12%
1 Year Change4.74%
33 Year Change-10.16%
5 Year Change5.80%
Change since IPO359.68%

Recent News & Updates

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Jun 11
Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

May 08
A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Recent updates

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Jun 11
Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

May 08
A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Apr 22
Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Mar 15
Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

Feb 16
Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

Jan 17
What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

Dec 22
Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24
Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Shareholder Returns

A128940KR PharmaceuticalsKR Market
7D6.1%7.0%2.2%
1Y4.7%20.0%11.0%

Return vs Industry: A128940 underperformed the KR Pharmaceuticals industry which returned 20% over the past year.

Return vs Market: A128940 underperformed the KR Market which returned 11% over the past year.

Price Volatility

Is A128940's price volatile compared to industry and market?
A128940 volatility
A128940 Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement3.8%
Market Average Movement4.9%
10% most volatile stocks in KR Market11.1%
10% least volatile stocks in KR Market2.3%

Stable Share Price: A128940 has not had significant price volatility in the past 3 months.

Volatility Over Time: A128940's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19732,238Jae-Hyun Parkwww.hanmipharm.com

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

Hanmi Pharm. Co., Ltd. Fundamentals Summary

How do Hanmi Pharm's earnings and revenue compare to its market cap?
A128940 fundamental statistics
Market cap₩3.64t
Earnings (TTM)₩158.09b
Revenue (TTM)₩1.53t

23.0x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A128940 income statement (TTM)
Revenue₩1.53t
Cost of Revenue₩684.71b
Gross Profit₩848.67b
Other Expenses₩690.59b
Earnings₩158.09b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)12.47k
Gross Margin55.35%
Net Profit Margin10.31%
Debt/Equity Ratio47.9%

How did A128940 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

4%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.